Moderna, Inc. (FRA:0QF)
Germany
· Delayed Price · Currency is EUR | Market Cap | 9.33B |
| Revenue (ttm) | 2.94B |
| Net Income (ttm) | -3.11B |
| Shares Out | n/a |
| EPS (ttm) | -8.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,280 |
| Average Volume | 47,890 |
| Open | 22.64 |
| Previous Close | 22.80 |
| Day's Range | 22.63 - 24.00 |
| 52-Week Range | 20.59 - 148.52 |
| Beta | n/a |
| RSI | 51.36 |
| Earnings Date | Jul 31, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Moderna wins FDA nod for next-gen COVID-19 shot
US approves new Moderna Covid jab for over-65s
WASHINGTON - The US Food and Drug Administration has approved Moderna’s next-generation Covid-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the r...
New Covid vaccine approved by US FDA: Here's all about it
The US FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, amidst emerging coronavirus variants. It is approved for adults 65 and older, and individuals aged 12-64 with underlying risk factors...
US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for all individuals aged 65 and above, the company said on Saturday, the first endorsement since the regul...
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has...
Trump Administration Cancels $600 Million Contract to Develop Bird Flu Vaccine
The administration cited concerns about mRNA technology; however, Moderna says the vaccine causes a "rapid, potent and durable immune response" to the virus
Moderna, Inc. (MRNA) Bernstein 41st Annual Strategic Decisions Conference Call Transcript
HHS cancels Moderna contract for development of bird flu vaccine for humans
The Department of Health and Human Services announced this week that it had canceled its contract with Moderna to develop a bird flu mRNA vaccine for humans. In a statement, the department wrote that ...
HHS cancels funding for Moderna vaccines to fight pandemic flu
The Department of Health and Human Services is cancelling hundreds of millions of dollars in funding pledged to Moderna to help the company develop, test, and license mRNA-based vaccines to combat pan...
Moderna Loses $700M US Contract for Bird Flu Vaccine Development
Moderna loses $700 million U.S. contract to develop bird flu vaccine after government review ends funding.
Trump administration cancels $766 million Moderna contract to fight future pandemics including bird flu
The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc.
HHS cancels Moderna bird flu deal
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
HHS cancels Moderna bird flu deal
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
Trump administration cancels $766 million contract with Moderna to develop vaccine against pandemic flu viruses
The new vaccine, called mRNA-1018, used the same technology that allowed development and rollout of vaccines to fight COVID-19 in record time.
Moderna steady while HHS ends pandemic flu vaccine contract
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort
The President Donald Trump administration terminated a nearly $600 million contract to Moderna Inc. (NASDAQ: MRNA) for developing an mRNA-based bird flu vaccine, ending a key former President Joe Bid...
Trump administration cuts $766 million in funding to Moderna for bird flu, pandemic vaccine projects
The Trump administration has withdrawn $766 million in funding from Moderna, impacting the development of vaccines against potential pandemic influenza viruses, including H5N1 bird flu. This decision ...
Trump Cancels More Than $700 Million Funding For Moderna Bird Flu Vaccine
The Trump administration has cancelled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, according to the drugmak...
HHS slams 'under-tested' mRNA technology as Trump cuts Moderna's vaccine funding
Trump HHS ends nearly $1 billion in funding to Moderna for mRNA bird flu vaccines, citing safety concerns and lack of oversight around the new mRNA vaccine technology.
US cancels more $700 million funding for Moderna bird flu vaccine
The Trump administration has cancelled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, according to the drugmak...
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim resultsCompany has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBR...
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMB...
Moderna to Present at Upcoming Conferences in June 2025
CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:Jefferies Global Health Care Conference, ...
Moderna to Present at Upcoming Conferences in June 2025
CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Jefferies Global Health Care Conference,...